Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

#TBT: Why Patient Differences Matter, Especially When It Comes to Cancer Treatments

November 13, 2014

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous research, videos or commentaries in a relevant way. As the saying goes, “what’s old is new again” – and we hope you enjoy our wonky twist on #TBT.

It’s a list that I wish would stop getting longer. It’s the list of people I know or have known who have battled cancer: breast cancer, leukemia, sarcoma, multiple myeloma, stomach cancer, brain cancer.

I think often about all of these relatives and friends, many of whom, thanks to modern medicine, are still here today. And I think about how they dealt with their cancers. The one thing they all have in common, if you could call it that, is the individuality or uniqueness of how they handled their treatments, not just from a clinical perspective, but from a social one as well.

Some sought the support of a network of close friends. Others told no one, but for their spouse, until after their treatments were completed. One close friend hired a medical team to research his tumor type and determine what course of treatment might work best. Another lived at Hope Lodge with her son while she underwent treatment in New York City. And they all followed different treatment regimens, with different side effects, and with different outcomes.

These differences are not only due to the type of cancer, but because of heterogeneity, or individual treatment effects. As the National Pharmaceutical Council explains on its website,

“Each person is unique thanks to a multitude of factors, such as racial and ethnic backgrounds, age, genetics, chronic conditions, disease severity, gender, environment, and even personal preferences when it comes to health treatments. These and other factors make patients different and affect how they may respond to a certain treatment. For these reasons, while the ‘average patient’ may respond best to a particular treatment, some patients may experience little to no benefit from it, so other treatment options may be best for them. These differences in how patients respond to treatments are known as ‘heterogeneity,’ or ‘individual treatment effects.’”

Dr. Darius Lakdawalla, Director of Research at the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California, explains this concept even more clearly in this video (and one of our two #TBT video picks):

When it comes to cancer treatments, it’s vital to get it right the first time; cancer patients don’t have the luxury of time to try a variety of treatment options. As Dr. Ellen Sigal, chairperson and founder of Friends of Cancer Research, with whom we spoke during our 2012 conference, explained in our second #TBT video pick, cancer patients need access to “the best and most effective treatment the first time. “They don’t want to have to fail two, three or four treatments.”

Thankfully, there are many scientists and researchers who are working on promising treatments, with more than 1,000 oncology medicines in development today. More than 80% of these oncology medicines are new approaches to targeting cancers, offering real hope that we may be getting closer to cures for certain cancers.

October 2014’s Breast Cancer Awareness Month is now behind us, but my relatives and friends who have fought cancer are a constant and ever-present reminder of how far we’ve come in understanding this disease, as well as how much further we still need to go.

Blog Post

Are We Getting the Right Data to Make Individualized Health Decisions? Maybe.

Personalized medicine—an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each...
Blog Post

ASCO’s Clinical Pathways Recommendations and Remaining Challenges

The American Society of Clinical Oncology (ASCO) today released its “policy statement on clinical pathways in oncology,” which acknowledges the...
Blog Post

#TBT: Great American Smokeout & the Future

As part of our Throwback Thursday blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous research...
Blog Post

#TBT: “Talk About Your Medicines” Month & A Question Checklist for Patients

As part of our Throwback Thursday blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous research...
Press Release

Michael Ciarametaro Joins National Pharmaceutical Council as Director of Research

Washington, DC (July 31, 2014)—The National Pharmaceutical Council (NPC) today announced that Michael Ciarametaro has joined the health policy...
Press Release

NPC Study Outlines When & How Health Decision-Makers Should Consider Individual Patient Differences

Washington, DC (July 29, 2014)—New research led by the National Pharmaceutical Council (NPC) can assist health care stakeholders to understand when...
Press Release

NPC, UMD Study: Factors That Cause Different Treatment Responses Are Not Well Understood or Studied

Washington, DC, November 4, 2013—Although researchers and health care providers widely recognize that individuals with stage IV prostate cancer react...
Press Release

National Pharmaceutical Council Comments on PCORI Approval of Research Methodology Standards

Washington, DC (November 19, 2012)—The National Pharmaceutical Council (NPC) today commented on the Patient-Centered Outcomes Research Institute’s (...
Commentary and Testimony Page

Chain Drug Review – Commentary: “Health Care Outlook for 2015”

This commentary was originally published in the January 5, 2015 issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Commentary and Testimony Page

NPC Comments on CMS' Proposed Changes to Protected Classes

March 7, 2014Marilyn B. TavennerAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services200 Independence...
Commentary and Testimony Page

Living Up to Its Name? The Role of Patient-Centered Research

Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...
Commentary and Testimony Page

The Risks of Standardized Health Care

Think about the last time you visited a medical office. Even at a specialist’s office, chances are that each person waiting for his or her name to be...
YouTube Videos

Using Distributed Data Networks to Understand Heterogeneity in Real-World Data

Kimberly Westrich, director of health services research at the National Pharmaceutical Council, explains how large observational datasets like...
YouTube Videos

Taking Patient Variations Into Account

Dr. Lisa Egbuonu-Davis, founder of ROI Squared, explains that data is generally designed toward looking at the mean differences instead of the...
YouTube Videos

Payer Views of Individualized Health Care

Dr. Daniel Malone, professor at the University of Arizona School of Pharmacy, explains how payers view the issue of individualized therapy. He says...
YouTube Videos

Dr. Puckrein on the Issue of Individual Patient Differences

Dr. Gary Puckrein, founder and president of the National Minority Quality Forum, says that there is tremendous variability in how different patients...
Blog Post

Are We Getting the Right Data to Make Individualized Health Decisions? Maybe.

Personalized medicine—an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each...
Blog Post

ASCO’s Clinical Pathways Recommendations and Remaining Challenges

The American Society of Clinical Oncology (ASCO) today released its “policy statement on clinical pathways in oncology,” which acknowledges the...
Blog Post

#TBT: Great American Smokeout & the Future

As part of our Throwback Thursday blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous research...
Blog Post

#TBT: “Talk About Your Medicines” Month & A Question Checklist for Patients

As part of our Throwback Thursday blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous research...
  •  
  • 1 of 4
  • >